Drug Profile
Barecetamab - ISU Abxis
Alternative Names: ISU-104Latest Information Update: 21 Jun 2023
Price :
$50
*
At a glance
- Originator ISU Abxis
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours; Squamous cell cancer
- Preclinical Breast cancer; Colorectal cancer
Most Recent Events
- 16 Jun 2023 Barecetamab is still in phase I trials for Solid tumors and Head and neck squamous cell carcinoma (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) in South Korea (ISU Axis pipeline, June 2023)
- 16 Jun 2023 Preclinical trials in Breast cancer in South Korea (Parenteral) (ISU Axis pipeline, June 2023)
- 16 Jun 2023 Preclinical trials in Colorectal cancer in South Korea (Parenteral) (ISU Axis pipeline, June 2023)